1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates


Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le mercredi 5 février 2020
Doi : 10.1016/j.jaad.2019.11.042
accepted : 22 November 2019
Botulinum toxin: Pharmacology and injectable administration for the treatment of primary hyperhidrosis

Shiri Nawrocki, BA a, , Jisun Cha, MD b
a Rutgers-Robert Wood Johnson Medical School, Department of Dermatology, Piscataway, New Jersey 
b Thomas Jefferson University, Department of Dermatology, Philadelphia, Pennsylvania 

Reprint requests: Shiri Nawrocki, BA, Department of Dermatology, Rutgers-Robert Wood Johnson Medical School, 675 Hoes Lane West, Piscataway, NJ 08854.Department of Dermatology, Rutgers-Robert Wood Johnson Medical School675 Hoes Lane WestPiscatawayNJ08854

Hyperhidrosis is a dermatological condition defined by excessive sweating beyond thermoregulatory needs with significant effects on patients' quality of life. Hyperhidrosis is categorized as primary or secondary: primary hyperhidrosis is mostly focal and idiopathic, whereas secondary hyperhidrosis is commonly generalized and caused by an underlying medical condition or use of medications. Various surgical and nonsurgical therapies exist for primary hyperhidrosis. Although botulinum toxin is one of the deadliest toxins known, when used in small doses, it is one of the most effective therapies for primary hyperhidrosis. Botulinum toxin injections are widely used as a second-line primary hyperhidrosis treatment option once topical treatment strategies have failed. This article provides an overview of the commercially available botulinum toxin formulations and their applications in the treatment of primary hyperhidrosis.

The full text of this article is available in PDF format.

Key words : abobotulinumtoxinA, axillary hyperhidrosis, botulinum neurotoxin, botulinum toxin, Clostridium bacteria, craniofacial hyperhidrosis, excessive sweating, incobotulinumtoxinA, onabotulinumtoxinA, palmar hyperhidrosis, plantar hyperhidrosis, primary hyperhidrosis, prabotulinumtoxinA, rimabotulinumtoxinB

Abbreviations used : BTX, FDA, HH, PHH

 Funding sources: None.
 Conflicts of interest: None disclosed.
 IRB approval status: Not applicable.

© 2020  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline